Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML
Bogdan Popescu(University of California, San Francisco), Catherine C. Smith(University of California, San Francisco)
Cited by 11
Related Papers
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
|Nature|2012|745
Travel-associated infection presenting in Europe (2008–12): an analysis of EuroTravNet longitudinal, surveillance data, and evaluation of the effect of the pre-travel consultation
|The Lancet Infectious Diseases|2014|248
Crenolanib is a selective type I pan-FLT3 inhibitor
|Proceedings of the National Academy of Sciences|2014|211
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations
|Blood Advances|2020|76
Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia
|bioRxiv (Cold Spring Harbor Laboratory)|2025|1